top of page


Our science is making news.
Stay in touch.

Follow us on LinkedIn.

Join our mailing list

Thanks for subscribing!

Medical oncologist & CMO at Transcenta joins the board of growing biotech company

February 16, 2023 ─ Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today that Caroline Germa, MD, a medical oncologist with more than two decades’ experience in the pharmaceutical industry, has joined its board of directors.

“With the addition of Dr. Germa’s expertise, we are uniquely positioned to accelerate our asset development from the preclinical stage,” said Ymmunobio Founder and CEO Katrin Rupalla. “We are honored that Dr. Germa has joined our Board and we look forward to working closely to advance our strategy for our novel and first-in-class antibody research.”

“I’m delighted to be joining Ymmunobio’s board,” said Dr. Germa. “The company’s assets represent a strong foundation of novel therapeutic antibodies, and its researchers have a deep understanding of the mechanisms of disease and the importance of cell-to-cell communication to create a response to cancer cells.”

Dr. Germa’s career spans the spectrum of drug development, from early clinical trials to late-phase and registration. Currently the Chief Medical Officer at Transcenta, a clinical-stage biotech company in both oncology and non oncology, Dr. Germa previously served as vice president and head of the Early Development Clinical Group for AstraZeneca’s oncology department. She has also worked for Bristol Myers Squibb as the Vice President and Development Team Lead for a major partnered oncology program and spent seven years at Novartis, where she led the late-phase clinical development of multiple key oncology assets, including the worldwide registration strategy and approval of Ribociclib (CDK4/6 inhibitor – Kisqali®).

Dr. Germa received her medical and medical oncology degrees from Paris and Lille University, France, as well as Breast Disease and Immunology Master Degrees.

Ymmunobio recently signed a transfer ownership agreement with Nagoya University for the license to NPTXR antibodies, which were invented by Professor Mitsuro Kanda, Department of Gastroenterological Surgery, Nagoya University, Japan. The company has begun developing the lead, fully humanized and first in class NPTXR antibody, YB-800, which has demonstrated anti-tumor activity in vivo and in vitro for solid tumors, including several gastro-intestinal and breast cancers.

To learn more about Ymmunobio’s activities and research, visit the website or reach out to

Growing preclinical-stage biotech company adds to executive team

RIEHEN, SWITZERLAND, February 8, 2023 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, has appointed Angela S. Gibbs, as its Chief Business Officer (CBO). The CBO role is a new position in which Gibbs will be responsible to assist in a strategy of growth for Ymmunobio and in cultivating relationships with potential partners and investors.

Gibbs has more than 15 years of experience in Life Science, building brands, managing business development, and advancing new market opportunities. She most recently served as Global Head, Strategic Marketing for Ascom Holding AG, where she led global brand stewardship, marketing transformation, and the repositioning of a new global Healthcare Platform solution.

“The addition of Angela’s expertise provides a strong support for Ymmunobio’s visibility and our transition through growth phases,” said Ymmunobio Founder and CEO Katrin Rupalla. “We’re delighted that she has joined our team with a commitment to help us realize the full vision of our asset development strategy.”

“I’m excited to help accelerate Ymmunobio’s robust growth,” said Gibbs. “The company has a remarkable portfolio of assets that are crucial for developing effective therapies for cancer, and I’m eager to share our vision with scientific and business stakeholders and investors. The work we’ll do together will be important for foundational and relationship building.”

Angela’s career has been focused on product portfolio leadership, defining new solution concepts, and delivering new-to-world technology across Product Management, New Product Innovation, and Strategic Marketing. Prior to relocating to Switzerland in 2014, Angela was Chief Marketing Officer at Surescripts USA, where she spearheaded primary research to frame strategy, product-market fit, and new capability-building investments to support market expansion and Marketing agility. She earned a Master of Business Administration from Harvard Business School.

To learn more about Ymmunobio’s activities and research, visit the website or reach out to


Ymmunobio AG is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.

Investor Relations: Dr. Katrin Rupalla,

Research indicates that NPTXR may have utility for treatment of gastro-intestinal cancers.

Read more here:

bottom of page